CDK6在早期卵巢癌中表达及其临床意义

Expression of CDK6 in early ovarian cancer and its clinical significance

目的探讨CDK6在早期卵巢癌组织中的表达及其临床意义。方法利用实时荧光定量PCR检测CDK6在卵巢癌以及卵巢组织中的表达;进一步,利用免疫组化检测CDK6蛋白在卵巢癌以及卵巢组织中的表达;统计分析CDK6在卵巢癌与卵巢组织中的表达差异;分析CDK6蛋白表达与临床参数以及生存预后的相关性。结果实时荧光定量PCR分析36例卵巢癌与16例卵巢组织中的CDK6 m RNA表达显示,与卵巢组织相比,CDK6 m RNA表达水平在卵巢癌组织中明显升高(P=0.0063);免疫组化分析121例卵巢癌和48例卵巢组织CDK6蛋白表达后显示,CDK6蛋白是一个核浆共表达因子,其表达水平在卵巢癌组织中明显高于卵巢组织(P=0.044)。除此之外,过表达的CDK6与卵巢癌组织临床参数无明显相关性,但与患者的预后呈明显负相关(P=0.006)。最后,多变量分析显示,CDK6是早期卵巢癌预后不良的一个独立因子(P=0.025)。结论 CDK6过表达作为不利的因素促进了早期卵巢癌发生发展。

Objective To explore the expression of CDK6 in early ovarian cancer and explore its clinical significance. Methods Real-time PCR and immunohistochemistry was used to examine the differential expression of CDK6 mRNA and protein in ovarian cancer and normal ovarian tissues. The correlation of CDK6 expression with the clinical characteristics and prognosis of the patients was analyzed. Results The expression of CDK6 mRNA was obviously up-regulated in 36 ovarian cancer tissues as compared to that in 16 ovarian tissues. Immunohistochemistry demonstrated that CDK6 protein was expressed in both the cytoplasm and cell nuclei. Compared with the 48 normal ovarian tissues, the 121 ovarian cancer tissues showed significantly up-regulated CDK6 protein expression （P=0.044）. Increased CDK6 protein expression was not significantly correlated with the clinical features of the patients with ovarian cancer, but showed a significant negative correlation with the patients＇ prognosis （P=0.006）. Multivariate analysis suggested that CDK6 expression level was an independent prognostic indicator （P=0.008） for the survival of patients with ovarian cancer. Conclusion Increased CDK6 protein expression may promote the development and progression of early ovarian cancer.